Key facts
- Byome Labs’s last known valuation is $14.7M (Sep 2025).
- It has raised $4.2M; the latest was Early Stage VC ($4.2M) in Sep 2025.
- Notable investors include Angels Santé, Paris Business Angels, Remora Biotech.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Byome Labs
- ·The full record, as it builds
Funding rounds
No funding rounds for Byome Labs are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Byome Labs
Operator of a microbiology laboratory intended to specialize in microbiota and microbiome testing and analysis for cosmetics. The company integrates in-vitro microbiology and rapid skin sampling technologies to assess microbiome conditions across skin, scalp, oral, and vaginal areas, and it delivers real-time compatibility analysis of cosmetic products, supports ingredient efficacy testing, and enables brands to offer personalized skincare routines at point-of-sale or at home, enabling cosmetic and dermocosmetic companies to develop products that promote skin health and meet evolving consumer and regulatory demands.
- Sector
- Healthcare
- HQ
- Le Coudray, France
- Founded
- 2023
- Employees
- 17
- Website
- byomelabs.com/
- Ownership
- Privately Held (backing)
Byome Labs doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Byome Labs shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Byome Labs in its N-PORT filings yet. We sweep new filings monthly.